Ossiam’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Ossiam’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,670	Closed	-$306K	–	525
2019 Q3	$306K	Sell	2,670 -3,942	-60%	-$392K	0.02%	282
2019 Q2	$630K	Hold	6,612	–	–	0.05%	186
2019 Q1	$603K	Sell	6,612 -16,714	-72%	-$1.37M	0.05%	161
2018 Q4	$1.77M	Buy	+23,326	New	+$1.72M	0.27%	95

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ossiam's CBPO Position: Q4 2019 in Review

Ossiam sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2019, closing a stake of 2,670 shares — an estimated $306K sold.

Ossiam first reported a position in CBPO in Q4 2018 and held it in 4 quarters. The position peaked at $1.77M in Q4 2018. 87 funds tracked by Wall St. Rank hold CBPO as of Q4 2019.

Ossiam reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2019 after selling out during the quarter.
Ossiam sold 2,670 China Biologic Products Holdings, Inc. shares in Q4 2019, an estimated $306K.
Ossiam first reported a position in China Biologic Products Holdings, Inc. in Q4 2018 and held it in 4 quarters.
Ossiam's China Biologic Products Holdings, Inc. position peaked at $1.77M in Q4 2018.
87 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2019.

Based on Ossiam's 13F filing for Q4 2019, filed 14 Feb 2020.